Kehe Chen

机构：The People's Hospital of Guangxi Zhuang Autonomous Region, Affiliated Hospital of Youjiang Medical University for Nationalities · ORCID：0000-0002-4334-1003

发表论文 21 篇 · 总被引 219 次 · h-index 9

代表论文

• Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial (2022 · British Journal of Cancer · 被引 32)
• Efficacy, Safety, and Immunogenicity of HLX04Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatmentfor Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase IIIStudy (2021 · BioDrugs · 被引 29)
• Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 20)
• Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells (2019 · European Journal of Pharmacology · 被引 20)
• First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial (2024 · Med · 被引 17)
• Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib (2020 · Frontiers in Oncology · 被引 17)